We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound
News

Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound

Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound
News

Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Re-Pharm Identifies Novel Anti-Inflammatory Activity for Existing Compound"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Re-Pharm has announced the identification of RP0217 as an effective new anti-inflammatory agent.

RP0217 is an existing drug which is widely prescribed for non-inflammatory conditions. The identification of this novel anti-inflammatory activity creates the opportunity to develop new non-steroidal approaches to the treatment of a variety of disease indications.

“Re-Pharm is dedicated to re-purposing compounds to address areas of unmet medical need,” says Dr Alan Rothaul, CSO at Re-Pharm. “Our streamlined method made it possible to move efficiently through pharmacological assessment, computational chemistry work and initial testing in order to demonstrate novel anti-inflammatory activity for an existing drug.”

“We are delighted with the discovery of RP0217 and look forward to its progression through clinical trials,” says Dr Robert Scoffin, CEO at Re-Pharm. “The filing of our first patents represents a significant validation of Re-Pharm’s approach to re-profiling and I look forward to many similar future successes.”

Advertisement